2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases: Radiotheragnostic Practicum

$63

15 Videos + 1 PDF
Categories: , ,

More Information About: 2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases: Radiotheragnostic Practicum

Course/Book Format:

15 Videos + 1 PDF

Course/Book Details (Overview + Topics/Speakers):

This continuing education activity reviews best practices in the growing field of radiotheragnostics (aka theranostics or theragnostics) for benign and malignant diseases, beginning with the fundamentals and extending to include advanced clinical applications. A review of historically established therapies that have been optimally modernized as well as the recently introduced state-of-the-art modalities are included. The expert faculty discuss the optimization of the radiotheragnostic practices for best utilization of various radiopharmaceuticals in contemporary health care delivery systems, both academic and private practice settings.

Target Audience 

This meeting is designed for nuclear medicine physicians, nuclear radiologists, oncologists, health physicists, and radiopharmacists.

Educational Objectives
At the completion of this CME activity, subscribers should be able to:

– The difference between the radiotheragnostic approach and various other concepts guiding the therapeutic delivery of radiation to the target tissues with the objective of improving health outcomes.
– The best therapeutic practice approaches to hyperthyroidism and other benign thyroid diseases, based on evidence and/or sound medical judgment.
– The best therapeutic practice approaches to differentiated thyroid carcinoma, based on evidence and/or sound medical judgment.
– The optimal applications of Y-90 Ibritumomab Tiuxetan for therapy of lymphoma.
– The optimal applications of I-131 Iobenguane to diagnostic imaging and therapy of Pheochromocytoma and Paraganglioma.
– The optimal applications of Y-90 Resin and Glass Microspheres to radioembolization therapy of liver cancers.
– The optimal applications of Ga-68 Dotatate Imaging and Lu-177 Dotatate therapy of neuroendocrine tumors.
– The optimal approach to diagnostic imaging of recurrent and metastatic prostate cancer.
– The best approach to therapy of skeletal metastatic disease using various Bone-Seeking radiopharmaceuticals.
– The practical examples for evaluation of not listed cancers for radiotheragnostics-based trials.
– Best approaches to building radiotheragnostic practice in academic institutions.
– Best approaches to building radiotheragnostic practice in private practice settings.

Topics/Speakers : 

History & Practice of Radioiodine Therapy in Hyperthyroidism
Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

Overview of Targeted Therapy – Lessons Learned
Terence Z. Wong, M.D., Ph.D.

Radioiodine Therapy: Uncommon Benign Thyroid Conditions
Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

I-131 Iobenguane Imaging & Therapy for Pheochromocytoma/Paraganglioma
Erik S. Mittra M.D., Ph.D.

Radioiodine in Thyroid Cancer – Basics
Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

Radioiodine in Thyroid Cancer – Advanced
Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

Radioembolization Therapy with Y-90 Resin and Glass Microspheres
Terence Z. Wong, M.D., Ph.D.

Ga-68/Lu-177 Dotatate Imaging/Therapy of Neuroendocrine Tumors
Erik S. Mittra M.D., Ph.D.

Diagnostic Imaging of Recurrent and Metastatic Prostate Cancer
Samuel Mehr, M.D.

Therapy for Skeletal Metastatic Disease with Bone-Seeking Agents
Terence Z. Wong, M.D., Ph.D.

Radiotheragnostics in Prostate Cancer
Terence Z. Wong, M.D., Ph.D.

Pivotal Trials in the USA for Up-and-Coming Radiotheragnostics
Erik S. Mittra M.D., Ph.D.

Opportunities for Somatostatin Receptor Targeting in Avid Cancers
Samuel Mehr, M.D.

Building Nuclear Medicine Therapy Program in Academic Practice
Erik S. Mittra M.D., Ph.D.

Building Nuclear Medicine Therapy Program in Private Practice
Samuel Mehr, M.D.

CME Release Date 2/14/2021

CME Expiration Date 2/14/2024

Target Audience and Covered Specialties:

DocMedED, Oncology, Radiology, simple

Delivery Method and Usage Instructions

After purchasing this product, Downloadable Link of 2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases: Radiotheragnostic Practicum course/book will be sent to Customer’s Email Address The Download Links Will NOT Expire, Can Be Used Anytime, Can be Downloaded on device for offline usage

———-

General Detail about CME Courses:

CME (Continuing medical education) Lectures helps to maintain competence and learn about new and developing areas of specialty. CME and Board Review Courses are the Best options for knowledge improvement and update. also you can use them to get best performance on your board exam.

  Important Notice  

after buying this product, you will be provided with Download Link to 2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases: Radiotheragnostic Practicum, Download Link DONT HAVE Expiry Time , you can use it anytime. Downloading The content is ALLOWED, you can easily save the product on your device.

Disclaimar

NO CME Credits and Accreditation will be issued
By Purchasing This course, you will receive all of the mentioned content as download link.
The Course link will not expire and is lifetime

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Shopping Cart